Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.

Kyoung Jin KimJimi ChoiJuneyoung LeeJae Hyun BaeJee Hyun AnHee Young KimHye Jin YooJi A SeoNan Hee KimKyung Mook ChoiSei Hyun BaikSin Gon KimNam Hoon Kim

Published in: Cardiovascular diabetology (2019)

This real-world database analysis showed that DPP4i therapy did not increase the overall risk of major cardiovascular and renal outcomes compared to SU therapy. However, the DPP4i-associated risk of HHF remained significant.

Keyphrases

stem cells
emergency department
adipose tissue
bone marrow